Background {#Sec1}
==========

Fractionated or single-dose radiotherapy to spinal metastases of solid tumors is one of the most frequently performed radiation treatments \[[@CR1]\]. Highly conformal radiation techniques such as Stereotactic Body Radiation Therapy (SBRT), Intensity Modulated Radiation Therapy (IMRT) or VMAT are increasingly being used as their application becomes easier and dose distributions confer theoretical advantages \[[@CR2]\], albeit so far without proof of superior clinical outcome. On the other hand, generation of an optimal IMRT or VMAT plan is often time consuming and it has been shown that staff limitations are correlated with restricted use of new techniques such as IMRT even in the developed world \[[@CR3], [@CR4]\]. Automated planning of IMRT and VMAT may reduce the workload which is associated with manual "trial-and-error" approaches by around 50% \[[@CR5]\].

Erasmus-iCycle, developed at the Erasmus MC-Cancer Institute, is an optimizer for multicriterial beam profile optimization and beam angle selection for coplanar and non-coplanar IMRT \[[@CR5]--[@CR10]\]. Other solutions for multicriterial beam angle optimization have been proposed by Schreibmann et al. \[[@CR11]\], Craft and Monz presented a full multibeam space Pareto navigation tool \[[@CR12]\]. However, both are *a posteriori* methods, i.e., the algorithm generates different sets of beam angles and intensity profiles from which the user selects the plan afterward. The Erasmus-iCycle solution is an a priori approach which enables the user to define a site specific set of criteria (wish-list) which may not be violated (constraints) or have to be met as well as possible, or better (objectives). Objectives have assigned priorities to steer the multicriterial planning towards favourable trade-offs between the various treatment goals. If the priority of an objective is higher, the probability that the corresponding objective is met increases. Hard constraints are always respected in Erasmus-iCycle plans.

Beam directions are selected from candidate directions which can be restricted, e.g., in case of coplanar treatments \[[@CR6], [@CR7], [@CR13]\]. For fully automated generation of plans that are clinically delivered, Erasmus-iCycle auto plans are automatically reconstructed and segmented in the clinical treatment planning system (TPS) \[[@CR13]\]. This study intends to validate VMAT plans for treatment of spinal metastases, generated with this approach, and to compare the quality of automatically generated plans with plans that were manually created by experienced treatment planners. Different spine regions pose different optimization problems as a consequence of different OARs being relevant for the treatment. Therefore cervical, thoracic, and lumbar targets were included in the study design.

Methods {#Sec2}
=======

Manual plan generation {#Sec3}
----------------------

Forty-two clinical target volumes (CTVs) in the spinal column of 32 patients were manually delineated for clinical routine treatments. CTVs were anisotropically expanded to PTVs that were the basis for all further analyses. All PTVs were reviewed by expert radiation oncologists (FW, FL).

Manual plans were created by expert treatment planners and also reviewed by radiation oncologists. All manually generated plans were calculated using the Monaco® treatment planning system (Elekta Ltd, Crawly, UK) version 3.2 or later which supports static IMRT, dynamic IMRT, and VMAT. Informed consent was obtained from all patients for anonymized processing of their clinical data. The study was approved by the ethics committee of Heidelberg University, Medical Faculty Mannheim (2016-806R-MA). For this study we assumed lungs or kidneys to be (potentially pre-irradiated) OARs, therefore we included only spinal regions which were at the level of kidneys (*n* = 22), lungs (*n* = 17), or both (*n* = 3), resulting in 90 (45\*2) OARs and 42 PTVs in total. Spinal reirradiation plans were not tested in this study; nevertheless, we contoured the spinal cord to identify any hotspots in this area within the target volume. Most plans were at the thoracic, thoracolumbar or lumbar level. In 4 cases, soft tissue metastases or rib metastases were included in the PTV. Prescribed doses ranged from 30 to 40 Gy in 10--20 fractions which are commonly applied treatment regimens in patients with sufficient life expectancy and good general condition (Eastern Cooperative Oncology Group, ECOG 0/1; Karnofsky Performance Status, KPS \> 80%). Generally, 40 Gy regimens were applied to patients who received postoperative radiotherapy. We did not include patients who had to be treated with spinal cord sparing plans after prior full dose irradiation of the spinal cord. While some patients had in fact received prior radiotherapy, this previous therapy did not require sparing of spinal cord to meet dose constraints \[[@CR14]\]. Details on irradiation sites are summarized in Table [1](#Tab1){ref-type="table"}. Further information such as primary tumor site of each patient is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1.Table 1Characteristics of spinal irradiation plans (*n* = 42)Number of sitesIrradiation siteCervical spineNoneCervical and thoracic spine2Thoracic spine^a^15Thoracic and lumbar spine17Thoracic and lumbar spine, Sacrum3Lumbar spine4Lumbar spine and Sacrum1Primary tumor siteBreast Cancer15Prostate Cancer11Lung Cancer5Non-Small Cell Lung Cancer3Small Cell Lung Cancer2Gastric and Oesophageal Cancer5Multiple Myeloma3Head and Neck1Unknown Primary1Urothelial Cell Carcinoma1Organs at riskKidneys22Lungs17Lungs and kidneys in one plan^b^3Median dose40Gy930Gy33Concerning PTV coverage, keeping the patients in both groups would have weighted these 3 plans double, therefore all statistics were recalculated under inclusion/exclusion of these patients. This did not change statistical significance in any case (i.e., only numerical changes occurred)^a^including 3 plans in which a rib metastasis was included into the irradiation field. In one plan a rib metastasis and a soft tissue metastatic site were included into the irradiation field^b^in 3 plans, lungs and kidneys were both considered OARs. For statistical considerations, these plans were evaluated in both groups concerning calculations for organs at risk

Automated VMAT plan generation with Erasmus-iCycle (auto) {#Sec4}
---------------------------------------------------------

Target volumes were identical to those used in the manual planning approach. General principles of iCycle plan generation are described above. Further details on auto-planning with the Erasmus-iCycle/Monaco system have been previously provided by Voet et al. \[[@CR5]\]. A site-specific wish-list for our patient cohort is shown in Additional file [2](#MOESM2){ref-type="media"}: Table S2. Apart from objectives for the PTV, the kidneys and the lungs, shells around the PTV are used to steer on conformality. Two cases were included which required beam restrictions, both because patients were unable to lift their arms.

Plan quality and statistical analysis {#Sec5}
-------------------------------------

Plan quality was estimated by calculating the dose to 98% (D~98%~) and to 2% (D~2%~) of the PTV. Both parameters were used to compute the homogeneity index (HI, \[[@CR15]\]) which was defined as the ratio between the difference of D~2%~ and D~98%~ and the median dose (D~50%~), i.e.,:$$\documentclass[12pt]{minimal}
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In addition, we calculated the volume receiving 95% of the prescribed dose (V~95%~ i.e., V~28.5Gy~, or V~38Gy~, depending if the prescribed dose was 30 Gy or 40 Gy), and based on V~95%~ a conformity index (CI, reviewed in \[[@CR15]\]) was calculated as follows:$$\documentclass[12pt]{minimal}
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An optimal CI would be considered to be 1; however, values can be above or below 1. To consider both over- and underdosage for statistical comparison of CI, we calculated the difference to 1 as follows:$$\documentclass[12pt]{minimal}
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For OARs, we calculated the mean dose (D~mean~), and in case of the spinal cord, the maximum dose to any hotspot (D~max~). All parameters were compared directly between manually generated plans and auto plans. Differences between variables were computed using the two-sample paired Wilcoxon test. Statistical significance was defined as p ≤ 0.05 (two-sided testing). Clinical acceptability of the plans was evaluated by an expert radiation oncologist (FL).

Results {#Sec6}
=======

All automatically created plans were clinically deliverable and acceptable. Figures [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} show dose distributions, and dose-volume histogram comparisons for a kidney-level target, and a lung-level target, respectively.Fig. 1**a** Dose distribution of a treatment plan on thoracolumbar level (T12-L2). The patient had metastatic breast cancer; irradiation dose applied with this plan was 30 Gy in 10 fractions. Manual plan shown on the left and auto plan on the right. **b** Dose-volume histogram at the same thoracolumbar level, continuous line represents manual plan, and dotted line represents auto plan Fig. 2**a** Dose distribution of a treatment plan on thoracic level (T7-T9). The patient had metastatic prostate cancer; irradiation dose applied with this plan was 30 Gy in 10 fractions. Manual plan shown on the left and auto plan on the right. **b** Dose-volume histogram at the same thoracic level, continuous line represents manual plan, and dotted line represents auto plan

Target volumes {#Sec7}
--------------

PTV coverage, defined as V~38Gy~ or V~28.5Gy~ was higher in auto plans when compared to manual plans when the whole patient population was analyzed, with an average difference of 1.47% (SD = 3.17%, *p* = 0.008, *n* = 42), see Fig. [3](#Fig3){ref-type="fig"}. When subgroups were analyzed, the difference was only significant in lung-level plans (*p* = 0.004, *n* = 20) but not at kidney levels (*p* = 0.110, *n* = 25). This pattern occurred irrespective whether 3 patients with both kidneys and lungs as OARs in one plan were added to the lung or to the kidney group or to both. Dose parameters were as follows: D~98%~ was numerically higher in auto plans when compared to manual plans but this was not statistically significant in the whole population (*p* = 0.479), nor in any subgroup (*p* \> 0.05 for both lung and kidney levels). D~2%~ was significantly higher in manual plans over the whole patient population (*p* \< 0.001), however the difference was clinically irrelevant (mean: 33.4 Gy vs. 33.2 Gy; median 31.1 Gy vs. 31.0 Gy). Subgroup analysis showed that D~2%~ was significantly lower in auto plans at kidney level (*p* = 0.003), however the difference was marginal and not clinically relevant. In lung-level plans, D~2%~ did not differ significantly between auto and manual plans.Fig. 3Volume receiving 95% of the prescribed dose, i.e., V~28.5Gy~ if prescribed dose was 30 Gy or V~38Gy~ if prescribed dose was 40 Gy

HI as defined above was not significantly different between auto and manual plans in the whole group or in any subgroup (*p* \> 0.05 for all comparisons). Considering the whole population, CI was slightly but statistically significant higher in auto plans than in manual plans: 1.014 ± 0.12 (1 SD) vs. 1.044 ± 0.11. For targets at the kidney level, the mean CIs for manual plans and auto plans were 0.99 ± 0.071 and 1.022 ± 0.067, respectively, and for lung-level targets 1.036 ± 0.157 and 1.065 ± 0.144. The differences between auto and manual plans can be explained by a slightly more pronounced underdosage in manual plans (minimum CI in manual plans: 0.88 \[kidney level\] and 0.81 \[lung level\]; minimum CI in auto plans: 0.92, and 0.95, respectively). C~diff~ did not differ significantly between auto and manual plans.

Organs at risk {#Sec8}
--------------

In the pooled analysis of all plans, mean dose to OARs (kidneys and lungs pooled) was significantly lower in auto plans when compared to manual plans on both the right side (*p* = 0.001, *n* = 45, relative difference -10.9% \[mean value auto vs. manual\]) and on the left side (*p* \< 0.001, *n* = 45, -19.5%). Subgroup analyses in patients with kidneys as OARs, including 3 patients with lungs and kidneys, showed that auto plans were associated with lower dose to both kidneys (*p* \< 0.001, *n* = 25, -18.6% right kidney, and *p* \< 0.001, *n* = 25, -23.1%, left kidney), see Fig. [4a](#Fig4){ref-type="fig"} for details. In lung-level plans, again including 3 plans in which both lungs and kidneys were included as OARs, only the left lung showed a significantly lower mean dose when auto-planning was used (*p* = 0.004, *n* = 20, -13.7%). Mean dose to the right lung did not differ significantly between manual and auto plans (*p* = 0.827, *n* = 20, -1.3%), see Fig. [4b](#Fig4){ref-type="fig"} for details. There was no significant difference between the maximum doses (D~max~) to the spinal cord between auto and manual groups in the whole population or in any subgroup. However, one patient in the auto group had a hotspot in the spinal cord (\>110% of prescribed dose: 33.2 Gy, D~50%~: 30 Gy).Fig. 4Comparison of mean dose to OARs. Each marker represents the mean dose in the manual plan vs. the auto plan to the kidneys (**a**) and to the lung (**b**). For data points right of the unity line, auto-planning yielded better sparing of OARs

Estimated treatment time and required monitor units {#Sec9}
---------------------------------------------------

Auto plans required slightly more (estimated) treatment time in the whole population (*p* \< 0.001, relative difference 7%) and in the subgroups of kidney-level (*p* \< 0.001, relative difference 9.7%), and lung-level plans (*p* = 0.046, relative difference 3.6%) as no hard constraint was placed on treatment time. This was a consequence of auto plans requiring more monitor units in the whole population and in any subgroup (p-values and relative differences as follows: whole population, *p* \< 0.001, 17.9%; kidney levels: *p* \< 0.001, 15.4%; lung levels: *p* = 0.001, 20.6%). All target volume information, monitor units, OAR dose values, and treatment times for each patient are also shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Discussion {#Sec10}
==========

Though highly conformal radiotherapy is not mandatory in the treatment of painful bone metastases \[[@CR16]\], intensity modulation with static beams or VMAT allows to deliver a highly focused dose distribution in every clinical situation and may be beneficial for patients with oligometastatic disease \[[@CR17]\] who require dose escalation or patients who had received prior courses of radiotherapy limiting doses to OARs in case of reirradiation \[[@CR18], [@CR19]\]. Highly conformal radiotherapy is, however, not always applied when appropriate \[[@CR3]\] for its perceived resource intensity, both in personnel and planning time. Unexpectedly, the reason for not performing advanced radiotherapy techniques despite a clear indication seems to be a shortage of sufficiently trained personnel rather than machine shortage \[[@CR3], [@CR4], [@CR20]\]. AlDuhaiby et al. described in a Canadian survey in 2012 that limitations in CT simulator or linear accelerator configuration impaired IMRT implementation in only 10% of cases \[[@CR20]\]. The most relevant factors hindering IMRT implementation was the need to train existent treatment planners (50%) as well as the need to hire more planners (30%) \[[@CR20]\]. Personal shortage is even more relevant in VMAT settings as these are more time consuming as compared to fixed field IMRT \[[@CR21]\]; "increased planning time required for generating the VMAT plans" has been described by Rao et al. as the main disadvantage of VMAT \[[@CR22]\]. Therefore, there is a need for tools that reduce planning time and ease the process of developing a radiotherapy plan without compromising plan quality.

Various auto-planning strategies are currently being developed \[[@CR8]\], these include approaches for beam angle selection (e.g., \[[@CR23]\]), and integrated beam weight optimization algorithms. The latter can be based on global optimization \[[@CR24]\], or on sequential beam selection \[[@CR25]\]. As discussed above, multicriterial optimization systems have been proposed \[[@CR11], [@CR12]\], that enable the user to select the plan out of different sets of beam angles and intensity profiles after optimization (*a posteriori* setting). Template based auto-planning solutions are already commercially available and have been applied to various target paradigms such as head and neck \[[@CR26]\], breast \[[@CR27]\] and esophageal targets \[[@CR28]\].

Erasmus-iCycle plans, which provide a template-free approach have been successfully applied to head and neck \[[@CR29]\], prostate \[[@CR5]\], and cervical cancer \[[@CR13]\] target volumes to create clinically deliverable plans.

Our results show that fully automated VMAT treatment planning with the Erasmus-iCycle/Monaco system for spinal metastases was non-inferior to conventional treatment planning by expert dosimetrists or medical physicists. Automatically generated plans with this system outperformed manual plans in terms of sparing of OARs in 3 of 4 predefined organs and also PTV coverage was favorable when compared to manual plans. We observed one hotspot in an iCycle plan in the spinal cord (33.2 Gy, D~50%~: 30 Gy). This problem can be addressed by modifying the wish list to include a maximum dose cost function on the spinal cord. In our analysis, however, we applied a quadratic overdose cost function which lead to maximum doses that were comparable to maximum doses observed in manual plans in all but this patient and allowed for more degrees of freedom regarding dose reduction to other OAR. If the maximum dose has to be strictly controlled, e.g., in case of reirradiation, a maximum dose cost function should be applied. Otherwise, the situation would be evaluated during the manual approval process which might prompt occasional replanning with a maximum dose cost function. Monitor units and estimated treatment time were higher in auto plans; however, this difference was not considered clinically relevant in the treated patient population and resulted in a negligible prolongation of treatment times. The difference in treatment times was expected as the aim of this study was to generate high-quality plans with clinically acceptable delivery times. Monitor units and delivery times could be reduced in the auto-plans if required. In contrast to a study in a more complex setting such as head and neck cancer \[[@CR29]\], the observed dosimetric advantages of Erasmus-iCycle for treatment of spinal metastases were on average of low clinical relevance although advantages across the population were also observed.

External audits have shown that experienced treatment centers may yield superior IMRT plans \[[@CR30]\]. Therefore, as postulated most recently by Fogliata et al. \[[@CR28]\], quality improvements of automated planning vs. manual plan generation may even be more pronounced in target paradigms that are not frequently treated in a particular center.

Conclusion {#Sec11}
==========

Our data add to the growing evidence \[[@CR5], [@CR13], [@CR29]\] that automated treatment planning might be an alternative to manual planning, reducing the workload of medical phyicists and dosimetrists while maintaining or improving plan quality.

Additional files {#Sec12}
================

Additional file 1:﻿Detailed comparison of auto- and manual planning results.﻿ (PDF 274 kb) Additional file 2:Wish list for automatic plan generation. (DOCX 26 kb)
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